Inhibrx reported registrational‑stage phase II results showing its monoclonal antibody ozekibart produced statistically significant and clinically meaningful progression‑free survival benefits in advanced or metastatic chondrosarcoma, a rare bone cancer with few options. The topline readout triggered a rapid market reaction and propelled company plans to pursue a Biologics License Application in 2026. The company signaled confidence in the data package and timelines for a regulatory submission, noting durable responses in a difficult‑to‑treat population. Investors and potential acquirers will watch the detailed dataset, safety profile, and FDA dialogue as Inhibrx prepares a formal filing strategy.